Trisilicate

Summary

Trisilicate (CHEMBL2109882) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 216.28 Da · H4O8Si3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109882
Name	Trisilicate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5311267
Molecular formula	H4O8Si3
Molecular weight	216.28
InChIKey	NPEYATQABYMBPM-UHFFFAOYSA-N

SMILES: O[Si](=O)O[Si](O)(O)O[Si](=O)O

IUPAC name: dihydroxy-bis[[hydroxy(oxo)silyl]oxy]silane

Parent form; salt/anhydrous children: CHEMBL2096633

Patent coverage: 62 distinct patent families (104 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).